Patients should be aware of important safety information: tirzepatide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Figure 3 below summarizes these processes, highlighting the interplay between bacterial infection, immune mediators (e.g., TNF-, IL-6, transforming growth factor-beta [TGF-], IL-10), and cellular actors (e.g., neutrophils, M1/M2 macrophages, fibroblasts, keratinocytes, endothelial cells) during wound healing [43, 48]
Patients may experience side effects such as gastrointestinal discomfort, and certain populations, such as those with pancreatitis or severe gastrointestinal disorders, may not be suitable candidates
Your journey begins with an in-depth consultation where our medical team evaluates your health history, weight loss goals, and eligibility for GLP-1 therapy
Since some compounding pharmacies may not be required to report adverse events, there is a lack of information on whether compounded semaglutide has the same interactions